A Safety Study of LY2886721 Multiple Doses in Healthy Subjects

Lilly

Status and phase: Completed; Phase 1

Conditions: Alzheimer's Disease

Treatments: Drug: Placebo; Drug: LY2886721

Study type: Interventional

Funder types: Industry

Identifiers

NCT01227252

I4O-MC-BACB (Other Identifier)

13734

Details and patient eligibility

About

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.

Enrollment: 42 patients

Sex: All

Ages: 20+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy men and non-childbearing potential women
• Body mass index between 18.0-32.0 kilograms per square meter (kg/m^2)
• Are reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures and research unit policies

Exclusion criteria

• Taking over-the-counter or prescription medication with the exception of vitamins or minerals
• Smoke more than 10 cigarettes per day
• Drink more than 5 cups of caffeine containing beverages (for example, coffee, tea) per day

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

42 participants in 2 patient groups, including a placebo group

LY2886721

Experimental group

Treatment:

Drug: LY2886721

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo